Exploring NASDAQ:AMPH's CANSLIM characteristics.

Groth investors are looking for stocks showing high revenue and EPS growth. We will have a look here to see if AMPHASTAR PHARMACEUTICALS IN (NASDAQ:AMPH) is suited for growth investing. Investors should of course do their own research, but we spotted AMPHASTAR PHARMACEUTICALS IN showing up in our CANSLIM growth screen, so it may be worth spending some more time on it.

Some of the canslim metrics of NASDAQ:AMPH highlighted

• In the most recent financial report, AMPHASTAR PHARMACEUTICALS IN reported a 203.0% increase in quarterly earnings compared to the previous quarter. This notable growth indicates positive momentum in the company's financials, suggesting an upward trend
• With impressive quarter-to-quarter (Q2Q) revenue growth of 50.37%, AMPHASTAR PHARMACEUTICALS IN showcases its ability to generate increased sales and revenue. This growth indicates the company's strong customer demand and its effective business strategies.
• AMPHASTAR PHARMACEUTICALS IN has achieved 77.88% growth in EPS over the past 3 years, reflecting a sustained improvement in earnings performance.
• AMPHASTAR PHARMACEUTICALS IN has a healthy Return on Equity(ROE) of 22.72%. This demonstrates the company's efficient utilization of capital and indicates its commitment to driving profitability.
• AMPHASTAR PHARMACEUTICALS IN has achieved an impressive Relative Strength (RS) rating of 97.33, showcasing its ability to outperform the broader market. This strong performance positions AMPHASTAR PHARMACEUTICALS IN as an attractive stock for potential price appreciation.
• AMPHASTAR PHARMACEUTICALS IN maintains a healthy Debt-to-Equity ratio of 1.07. This indicates the company's conservative capital structure and signifies its ability to effectively manage debt obligations while maintaining a strong equity position.
• With institutional shareholders at 66.59%, AMPHASTAR PHARMACEUTICALS IN demonstrates a healthy ownership distribution. This reflects a mix of institutional and individual investors, creating a market environment that may foster increased trading activity and price discovery.

In-Depth Technical Analysis of NASDAQ:AMPH

ChartMill assigns a Technical Rating to every stock. This score ranges from 0 to 10 and is updated daily. The score is determined by evaluating multiple technical indicators and properties.

Overall AMPH gets a technical rating of 10 out of 10. Both in the recent history as in the last year, AMPH has proven to be a steady performer, scoring decent points in every aspect analyzed.

• The long and short term trends are both positive. This is looking good!
• Looking at the yearly performance, AMPH did better than 97% of all other stocks. On top of that, AMPH also shows a nice and consistent pattern of rising prices.
• AMPH is one of the better performing stocks in the Pharmaceuticals industry, it outperforms 96% of 204 stocks in the same industry.
• AMPH is currently trading in the upper part of its 52 week range. The S&P500 Index however is currently trading near a new high, so AMPH is lagging the market slightly.
• In the last month AMPH has a been trading in the 44.42 - 61.20 range, which is quite wide. It is currently trading near the high of this range.

For an up to date full technical analysis you can check the technical report of AMPH

What else is there to say on the fundamentals of NASDAQ:AMPH?

As part of its analysis, ChartMill provides a comprehensive Fundamental Rating for each stock. This rating, ranging from 0 to 10, is updated on a daily basis and is based on the evaluation of various fundamental indicators and properties.

We assign a fundamental rating of 7 out of 10 to AMPH. AMPH was compared to 204 industry peers in the Pharmaceuticals industry. AMPH has an excellent profitability rating, but there are some minor concerns on its financial health. An interesting combination arises when we look at growth and value: AMPH is growing strongly while it also seems undervalued. With these ratings, AMPH could be worth investigating further for value and growth investing!.

Check the latest full fundamental report of AMPH for a complete fundamental analysis.

Our CANSLIM screen will find you more ideas suited for growth investing.

Keep in mind

Important Note: The content of this article is not intended as trading advice. It is essential to perform your own analysis and exercise caution when making trading decisions. The article presents observations created by automated analysis but does not guarantee any trading or investment outcomes. Always trade responsibly and make independent judgments.